A complete response letter for Sarepta’s follow-on Duchenne therapy is a big blow for the company, but in hindsight was the FDA’s decision actually that surprising?
The failure of its lead product in diabetic macular oedema, a limited pipeline and limited cash leaves Oxurion with few options.
Astrazeneca gets a win for its SGLT2 in heart failure irrespective of diabetes status, but Lilly and Boehringer’s Jardiance isn’t far behind.
Intuitive Surgical makes the most money per employee – but the title of “most improved” goes to Philips.
Reata Pharmaceuticals will soon find out if its decision to persevere with omaveloxolone despite an earlier failure has paid off.
The Medicines Company needs to show decent efficacy and pristine safety with its long-lasting PCSK9 inclisiran to stand a chance of disrupting the market.
The recent disappointing sales of drug-coated devices for peripheral arterial disease look likely to become the norm.
Software can be a medical device. Can it also be a drug?
Alcohol kills – and in this case, that could be a good thing.
Medtronic decides that Solitaire is best played with a partner.